1-17 of 17
Victor S. Goldmacher
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 667: IMGN853, a folate receptor (FR) α-targeting antibody-drug conjugate (ADC), is highly effective against xenograft models with clinically relevant levels of receptor expression

Olga Ab, Laura M. Bartle, Xiuxia Sun, Rui Wu, Holly A. Johnson, Kathleen R. Whiteman, Alyssa LaBelle, Victor S. Goldmacher
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 667.
https://doi.org/10.1158/1538-7445.AM2014-667
Published: 01 October 2014
View article titled, Abstract 667: IMGN853, a folate receptor (FR) α-targeting antibody-drug conjugate (ADC), is highly effective against xenograft models with clinically relevant levels of receptor expression
Journal Articles

Abstract 5677: A comparative study of the interaction of the maytansinoid, DM1-Me, vinblastine, and taxol with human cells

Charlene Audette, Yelena Kovtun, Victor S. Goldmacher
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 5677.
https://doi.org/10.1158/1538-7445.AM2012-5677
Published: 15 April 2012
View article titled, Abstract 5677: A comparative study of the interaction of the maytansinoid, DM1-Me, vinblastine, and taxol with human cells
Journal Articles

Abstract 4576: IMGN853, an anti-Folate Receptor I antibody-maytansinoid conjugate for targeted cancer therapy

Olga Ab, Laura M. Bartle, Lingyun Rui, Jennifer Coccia, Holly A. Johnson, Kathleen R. Whiteman, Brenda Kellogg, Lauren Clancy, Xiuxia Sun, Victor S. Goldmacher
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 4576.
https://doi.org/10.1158/1538-7445.AM2011-4576
Published: 15 April 2011
View article titled, Abstract 4576: IMGN853, an anti-Folate Receptor I antibody-maytansinoid conjugate for targeted cancer therapy
Journal Articles

Abstract 3617: Evaluation of folate receptor 1 (FOLR1) expression by calibrated immunohistochemistry identifies candidate tumor subtypes for targeting by IMGN853, an anti-FOLR1-maytansinoid conjugate

Christina N. Carrigan, Shanqin Xu, Klaudia Foley, Olga Ab, Victor S. Goldmacher, Gillian Payne
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 3617.
https://doi.org/10.1158/1538-7445.AM2011-3617
Published: 15 April 2011
View article titled, Abstract 3617: Evaluation of folate receptor 1 (FOLR1) expression by calibrated immunohistochemistry identifies candidate tumor subtypes for targeting by IMGN853, an anti-FOLR1-maytansinoid conjugate
Journal Articles

Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance

Yelena V. Kovtun, Charlene A. Audette, Michele F. Mayo, Gregory E. Jones, Heather Doherty, Erin K. Maloney, Hans K. Erickson, Xiuxia Sun, Sharon Wilhelm, Olga Ab, Katharine C. Lai, Wayne C. Widdison, Brenda Kellogg, Holly Johnson, Jan Pinkas, Robert J. Lutz, Rajeeva Singh, Victor S. Goldmacher, Ravi V.J. Chari
Journal: Cancer Research
Cancer Res (2010) 70 (6): 2528–2537.
https://doi.org/10.1158/0008-5472.CAN-09-3546
Published: 14 March 2010
View article titled, Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
Open the PDF for Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance in another window
Includes: Supplementary data
Journal Articles

Folate Receptor–Specific Antitumor Activity of EC131, a Folate-Maytansinoid Conjugate

Joseph A. Reddy, Elaine Westrick, Hari K.R. Santhapuram, Stephen J. Howard, Michael L. Miller, Marilynn Vetzel, Iontcho Vlahov, Ravi V.J. Chari, Victor S. Goldmacher, Christopher P. Leamon
Journal: Cancer Research
Cancer Res (2007) 67 (13): 6376–6382.
https://doi.org/10.1158/0008-5472.CAN-06-3894
Published: 06 July 2007
View article titled, Folate Receptor–Specific Antitumor Activity of EC131, a Folate-Maytansinoid Conjugate
Open the PDF for Folate Receptor–Specific Antitumor Activity of EC131, a Folate-Maytansinoid Conjugate in another window
Journal Articles

Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing

Hans K. Erickson, Peter U. Park, Wayne C. Widdison, Yelena V. Kovtun, Lisa M. Garrett, Karen Hoffman, Robert J. Lutz, Victor S. Goldmacher, Walter A. Blättler
Journal: Cancer Research
Cancer Res (2006) 66 (8): 4426–4433.
https://doi.org/10.1158/0008-5472.CAN-05-4489
Published: 17 April 2006
View article titled, Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing
Open the PDF for Antibody-Maytansinoid Conjugates Are Activated in Targeted Cancer Cells by Lysosomal Degradation and Linker-Dependent Intracellular Processing in another window
Includes: Supplementary data
Journal Articles

Antibody-maytansinoid conjugates are potent anti-cancer agents that are activated in the lysosome and arrest cancer cells in G2/M phase of the cell cycle in tissue culture and in xenograft tumor models

Peter U. Park, Anna Skaletskaya, Linda Hylander, Kate Connors, Michele Mayo, Thomas Chittenden, Victor S. Goldmacher
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 277–278.
Published: 15 April 2006
View article titled, Antibody-maytansinoid conjugates are potent anti-cancer agents that are activated in the lysosome and arrest cancer cells in G<sub>2</sub>/M phase of the cell cycle in tissue culture and in xenograft tumor models
Journal Articles

Antibody-Drug Conjugates Designed to Eradicate Tumors with Homogeneous and Heterogeneous Expression of the Target Antigen

Yelena V. Kovtun, Charlene A. Audette, Yumei Ye, Hongsheng Xie, Mary F. Ruberti, Sara J. Phinney, Barbara A. Leece, Thomas Chittenden, Walter A. Blättler, Victor S. Goldmacher
Journal: Cancer Research
Cancer Res (2006) 66 (6): 3214–3221.
https://doi.org/10.1158/0008-5472.CAN-05-3973
Published: 15 March 2006
View article titled, Antibody-Drug Conjugates Designed to Eradicate Tumors with Homogeneous and Heterogeneous Expression of the Target Antigen
Open the PDF for Antibody-Drug Conjugates Designed to Eradicate Tumors with Homogeneous and Heterogeneous Expression of the Target Antigen in another window
Journal Articles

HuC242-DM4, an antibody-maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice

Robert J. Lutz, Hongsheng Xie, Wayne C. Widdison, Peter S. Wunderli, Rita M. Steeves, Victor S. Goldmacher, John M. Lambert, Ravi V. J. Chari
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 334–335.
Published: 01 May 2005
View article titled, HuC242-DM4, an antibody-maytansinoid conjugate with superior preclinical activity in human CanAg-positive tumor xenograft models in SCID mice
Journal Articles

p53 Status Affects the Rate of the Onset but not the Overall Extent of Doxorubicin-induced Cell Death in Rat-1 Fibroblasts Constitutively Expressing c-Myc

Jia-wen Han, Cheryl A. Dionne, Nancy L. Kedersha, Victor S. Goldmacher
Journal: Cancer Research
Cancer Res (1997) 57 (1): 176–182.
Published: 01 January 1997
View article titled, p53 Status Affects the Rate of the Onset but not the Overall Extent of Doxorubicin-induced Cell Death in Rat-1 Fibroblasts Constitutively Expressing c-Myc
Open the PDF for p53 Status Affects the Rate of the Onset but not the Overall Extent of Doxorubicin-induced Cell Death in Rat-1 Fibroblasts Constitutively Expressing c-Myc in another window
Journal Articles

Enhancement of the Selectivity and Antitumor Efficacy of a CC-1065 Analogue through Immunoconjugate Formation

Ravi V. J. Chari, Kristine A. Jackel, Lizabeth A. Bourret, Susan M. Derr, B. Mitra Tadayoni, Kristin M. Mattocks, Sudhir A. Shah, Changnian Liu, Walter A. Blättler, Victor S. Goldmacher
Journal: Cancer Research
Cancer Res (1995) 55 (18): 4079–4084.
Published: 01 September 1995
View article titled, Enhancement of the Selectivity and Antitumor Efficacy of a CC-1065 Analogue through Immunoconjugate Formation
Open the PDF for Enhancement of the Selectivity and Antitumor Efficacy of a CC-1065 Analogue through Immunoconjugate Formation in another window
Journal Articles

Anti-B4-blocked Ricin Immunotoxin Shows Therapeutic Efficacy in Four Different SCID Mouse Tumor Models

Sudhir A. Shah, Patricia M. Halloran, Cynthia A. Ferris, Beth A. Levine, Lizabeth A. Bourret, Victor S. Goldmacher, Walter A. Blättler
Journal: Cancer Research
Cancer Res (1993) 53 (6): 1360–1367.
Published: 01 March 1993
View article titled, Anti-B4-blocked Ricin Immunotoxin Shows Therapeutic Efficacy in Four Different SCID Mouse Tumor Models
Open the PDF for Anti-B4-blocked Ricin Immunotoxin Shows Therapeutic Efficacy in Four Different SCID Mouse Tumor Models in another window
Journal Articles

Correspondence re: S. M. Bronstein et al. Efficient Repair of O6-Ethylguanine, but not O4-Ethylthymine or O2-Ethylthymine, Is Dependent upon O6-Alkylguanine-DNA Alkyltransferase and Nucleotide Excision Repair Activities in Human Cells. Cancer Res., 52: 2008–2011, 1992

Victor S. Goldmacher
Journal: Cancer Research
Cancer Res (1992) 52 (24): 6983–6984.
Published: 01 December 1992
View article titled, Correspondence re: S. M. Bronstein <em>et al.</em> Efficient Repair of <em>O</em><sup>6</sup>-Ethylguanine, but not <em>O</em><sup>4</sup>-Ethylthymine or <em>O</em><sup>2</sup>-Ethylthymine, Is Dependent upon <em>O</em><sup>6</sup>-Alkylguanine-DNA Alkyltransferase and Nucleotide Excision Repair Activities in Human Cells. Cancer Res., <em>52:</em> 2008–2011, 1992
Open the PDF for Correspondence re: S. M. Bronstein <em>et al.</em> Efficient Repair of <em>O</em><sup>6</sup>-Ethylguanine, but not <em>O</em><sup>4</sup>-Ethylthymine or <em>O</em><sup>2</sup>-Ethylthymine, Is Dependent upon <em>O</em><sup>6</sup>-Alkylguanine-DNA Alkyltransferase and Nucleotide Excision Repair Activities in Human Cells. Cancer Res., <em>52:</em> 2008–2011, 1992 in another window
Journal Articles

Correlation between in Vivo Toxicity and Preclinical in Vitro Parameters for the Immunotoxin Anti-B4-blocked Ricin

Michael L. Grossbard, John M. Lambert, Victor S. Goldmacher, Walter A. Blättler, Lee M. Nadler
Journal: Cancer Research
Cancer Res (1992) 52 (15): 4200–4207.
Published: 01 August 1992
View article titled, Correlation between <em>in Vivo</em> Toxicity and Preclinical <em>in Vitro</em> Parameters for the Immunotoxin Anti-B4-blocked Ricin
Open the PDF for Correlation between <em>in Vivo</em> Toxicity and Preclinical <em>in Vitro</em> Parameters for the Immunotoxin Anti-B4-blocked Ricin in another window
Journal Articles

Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs

Ravi V. J. Chari, Bridget A. Martell, Jonathan L. Gross, Sherrilyn B. Cook, Sudhir A. Shah, Walter A. Blättler, Sara J. McKenzie, Victor S. Goldmacher
Journal: Cancer Research
Cancer Res (1992) 52 (1): 127–131.
Published: 01 January 1992
View article titled, Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs
Open the PDF for Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs in another window
Journal Articles

An Immunotoxin Prepared with Blocked Ricin: A Natural Plant Toxin Adapted for Therapeutic Use

John M. Lambert, Victor S. Goldmacher, Albert R. Collinson, Lee M. Nadler, Walter A. Blättler
Journal: Cancer Research
Cancer Res (1991) 51 (23_Part_1): 6236–6242.
Published: 12 January 1991
View article titled, An Immunotoxin Prepared with Blocked Ricin: A Natural Plant Toxin Adapted for Therapeutic Use
Open the PDF for An Immunotoxin Prepared with Blocked Ricin: A Natural Plant Toxin Adapted for Therapeutic Use in another window